Clinical Telepathology Guidelines Available for Open Comment

I was honored to be a part of the American Telemedicine Association (ATA) work group, as an industry representative, to create an updated version of the 1999 Clinical Telepathology Guidelines.  Over the past 18+ months an excellent team, lead ...
Read more

HER2 Protein Expression in Breast Cancer: Membrane Morphology and Accuracy with Regard to Gene Amplification

Join Visiopharm for our webinar, “HER2 Protein Expression in Breast Cancer: Membrane Morphology and Accuracy with Regard to Gene Amplification” presented by Michael Grunkin, PhD the CEO and co-founder of Visiopharm. Date:    ...
Read more

Visiopharm’s Resourceful Resource Center: Our Publication Database

Over the past 4 years Visiopharm has collected references to over 600 scientific publications using our software within the areas of image analysis and stereology for quantitative histomorphometry with whole slide scanners and/or microscopes.  ...
Read more

Part 2: Why Some Pathologists Are Skeptical Of Digital Pathology – Can We Change That?

Last week I discussed in Part 1 the Gartner-Hype Cycle related to digital pathology and some of the objections we face.  But before we can move into the adoption phase of “Plateau of Productivity,” we need to re-think a few things about dig...
Read more

Part 1: Why Some Pathologists are Skeptical of Digital Pathology – Can We Change That?

Any digital pathology professional that actually sits down and watches the speed and dexterity with which a pathologist places a glass slide under the microscope, and then proceed to provide a diagnostic interpretation, must feel a little humbled: Ho...
Read more

Tumor Heterogeneity: Is There Order in Variety?

Where order in variety we see, and where, though all things differ, all agree. When Alexander Pope wrote those lines in 1734 in his “Essay on Man” he most certainly did not have tumor heterogeneity in mind. Perhaps now, almost 300 years ...
Read more